SNM Annual Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     




J Nucl Med. 2008; 49 (Supplement 1):41P
This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Gulenchyn, K.
PubMed
Right arrow Articles by Gulenchyn, K.

General Clinical Specialties: Operations/Practice Based/Outcomes Research

Siemens Award for Excellence in Practice Based Research

Ontario oncology trials to evaluate the clinical and economic impact of 18-FDG PET

Karen Gulenchyn1, Donna Maziak2, Gail Darling3, Tulay Koru-Sengul1, Mark Levine1 Ontario Clinical Oncology Group

1 McMaster, Hamilton, Ontario, Canada; 2 Ottawa Hospital, Ottawa, Ontario, Canada; 3 UHN, Toronto, Ontario, Canada

164

Objectives: In 2002 Ontario determined that there was insufficient evidence on the utility of FDG PET to proceed to widespread implementation; five trials were designed to inform decision making. We report the results of 1 of the 2 completed trials.

Methods: ELPET is a randomized control trial (RCT) of patients with Stage I to IIIA non small cell lung cancer (NSCLC) comparing conventional imaging (C) [CT abdomen including liver and adrenals, bone scan and cranial imaging] to PET/CT (P) plus cranial imaging.

Results: 337 patients were enrolled from 8 centres between July 2004 and August 2007; 167 in the C-arm and 170 in the P-arm. 17 patients (10 on C and 7 on P) were excluded from the analysis for protocol violations. The mean age was 66 years and 50% were male. Twenty-three (14%) of 163 patients in the P-arm were correctly upstaged and avoided inappropriate surgery compared to 11 (7%) of 157 in the C-arm, p=0.046 Fisher’s exact, 95% CI for the 7% risk difference, 0.03% to14%.

Conclusions: In NSCLC, staging with PET/CT better identifies those patients with mediastinal and extrathoracic disease, sparing some from stage-inappropriate surgery. The 3 previously published RCTs tested the addition of P to C, whereas we compared P with C. Our study shows that P can replace C in early stage NSCLC. This strategy has an economic impact by avoiding costs related to unnecessary surgery and those for staging abdominal CT and bone scan (about $1100/case in Ontario) and impacts on patient safety by avoiding CT-associated radiation exposure and nephrotoxicity. PET/CT imaging for the preoperative assessment of potentially resectable NSCLC is now being used widely in Ontario.

Research Support: Ontario Ministry of Health and Long Term Care





This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Gulenchyn, K.
PubMed
Right arrow Articles by Gulenchyn, K.